Exact Sciences Co. (NASDAQ:EXAS) Shares Bought by Peregrine Capital Management LLC

Peregrine Capital Management LLC increased its position in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 17.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 658,703 shares of the medical research company's stock after acquiring an additional 96,778 shares during the quarter. Exact Sciences makes up about 1.5% of Peregrine Capital Management LLC's portfolio, making the stock its 14th biggest holding. Peregrine Capital Management LLC owned approximately 0.36% of Exact Sciences worth $48,731,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of EXAS. Segall Bryant & Hamill LLC lifted its position in Exact Sciences by 4.7% in the second quarter. Segall Bryant & Hamill LLC now owns 3,315 shares of the medical research company's stock valued at $311,000 after buying an additional 150 shares during the last quarter. Harbour Investments Inc. lifted its position in Exact Sciences by 0.6% in the first quarter. Harbour Investments Inc. now owns 26,279 shares of the medical research company's stock valued at $1,782,000 after buying an additional 162 shares during the last quarter. Strategic Blueprint LLC lifted its position in Exact Sciences by 3.1% in the third quarter. Strategic Blueprint LLC now owns 5,449 shares of the medical research company's stock valued at $372,000 after buying an additional 163 shares during the last quarter. Green Alpha Advisors LLC lifted its position in Exact Sciences by 3.5% in the third quarter. Green Alpha Advisors LLC now owns 4,893 shares of the medical research company's stock valued at $334,000 after buying an additional 165 shares during the last quarter. Finally, Fulton Bank N.A. lifted its position in Exact Sciences by 3.4% in the third quarter. Fulton Bank N.A. now owns 5,335 shares of the medical research company's stock valued at $364,000 after buying an additional 176 shares during the last quarter. Institutional investors and hedge funds own 88.82% of the company's stock.

Exact Sciences Stock Up 4.1 %

Exact Sciences stock traded up $2.93 during mid-day trading on Tuesday, hitting $74.26. The company had a trading volume of 2,566,633 shares, compared to its average volume of 2,251,479. The stock has a market cap of $13.48 billion, a price-to-earnings ratio of -65.14 and a beta of 1.25. Exact Sciences Co. has a 1 year low of $56.05 and a 1 year high of $100.77. The company has a quick ratio of 2.07, a current ratio of 2.32 and a debt-to-equity ratio of 0.74. The business has a fifty day moving average of $62.78 and a 200 day moving average of $65.06.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last announced its quarterly earnings results on Wednesday, February 21st. The medical research company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.26. The company had revenue of $646.89 million for the quarter, compared to analyst estimates of $638.83 million. Exact Sciences had a negative net margin of 8.17% and a negative return on equity of 6.60%. The firm's revenue was up 17.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.72) earnings per share. On average, sell-side analysts expect that Exact Sciences Co. will post -0.86 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Kevin T. Conroy sold 14,791 shares of the stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $61.43, for a total value of $908,611.13. Following the completion of the sale, the chief executive officer now directly owns 1,224,357 shares of the company's stock, valued at $75,212,250.51. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Kevin T. Conroy sold 14,791 shares of the stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $61.43, for a total value of $908,611.13. Following the completion of the sale, the chief executive officer now directly owns 1,224,357 shares of the company's stock, valued at $75,212,250.51. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel James Herriott sold 415 shares of the stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $61.50, for a total value of $25,522.50. Following the completion of the sale, the general counsel now directly owns 6,943 shares of the company's stock, valued at $426,994.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 69,113 shares of company stock valued at $4,165,273. 1.30% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Benchmark raised shares of Exact Sciences from a "hold" rating to a "buy" rating and set a $91.00 target price on the stock in a research report on Tuesday, January 2nd. Canaccord Genuity Group decreased their target price on shares of Exact Sciences from $100.00 to $90.00 and set a "buy" rating on the stock in a research report on Thursday, February 22nd. TheStreet lowered shares of Exact Sciences from a "c-" rating to a "d+" rating in a research note on Monday, February 26th. Guggenheim started coverage on shares of Exact Sciences in a research note on Thursday, December 14th. They set a "buy" rating and a $90.00 price target on the stock. Finally, William Blair reiterated an "outperform" rating on shares of Exact Sciences in a research note on Thursday, February 22nd. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $97.44.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.